Unknown

Dataset Information

Modulation of oxidative phosphorylation augments antineoplastic activity of mitotic aurora kinase inhibition.


ABSTRACT: Uncontrolled mitosis is one of the most important features of cancer, and mitotic kinases are thought to be ideal targets for anticancer therapeutics. However, despite numerous clinical attempts spanning decades, clinical trials for mitotic kinase-targeting agents have generally stalled in the late stages due to limited therapeutic effectiveness. Alisertib (MLN8237) is a promising oral mitotic aurora kinase A (AURKA, Aurora-A) selective inhibitor, which is currently under several clinical evaluations but has failed in its first Phase III trial due to inadequate efficacy. In this study, we performed genome-wide CRISPR/Cas9-based screening to identify vulnerable biological processes associated with alisertib in breast cancer MDA-MB-231 cells. The result indicated that alisertib treated cance

SUBMITTER: Zhang Z 

PROVIDER: S-EPMC8484571 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature